Scholarlink

Introduction <p>Ulcerative colitis (UC) is the main representative of inflammatory bowel diseases (IBD) are chronic conditions characterized by intestinal inflammation, caused by the overproduction of pro-oxidant species and an immune response that damages the gut mucosa.</p> Objective <p>To evaluate the anti-inflammatory and protective effect of Citral, a monoterpene, on in vitro and in vivo models of UC.</p> Methodology <p>Male C57BL/6J mice were used for DSS 3%-induced UC for 5 days in drinking water. Concomitantly, daily oral citral (25, 100, and 300&#xa0;mg/kg, p.o.) or vehicle was administered. Colonic segments were collected to evaluate neutrophil infiltration, lipid peroxidation, and the expression of antioxidant markers. NCM-356 and RAW-294 cells were stimulated with LPS (10 and 100 ng/mL, respectively). Cell viability, nitrite levels, scratch wound healing assay, and gene expression of inflammatory and growth factors were assessed.</p> Results <p>Acute treatment with citral (100 and 300&#xa0;mg/kg) exhibited an anti-colitis effect by reducing the disease activity index (DAI) score compared to that in the DSS-vehicle group. This response was mediated by a significant reduction in myeloperoxidase activity and thiobarbituric acid reactive species levels, associated with an increase in superoxide dismutase activity, indicating anti-inflammatory and antioxidant activities (<i>p</i> &lt; 0.05). The monoterpene reversed LPS-induced intestinal epithelial disturbance in the scratch wound healing process under different conditions and possibly reduced <i>inos</i> expression.</p> Conclusion <p>Citral treatment prevents the development of UC via anti-inflammatory, antioxidant, and healing effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Citral impairs intestinal changes caused by ulcerative colitis through modulation of antioxidant, anti-inflammatory and healing activities

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Maycon T. Emílio-Silva,
  • Vinícius P. Rodrigues,
  • Antonio J. Ruiz-Malagon,
  • Isabela G. Guidolin,
  • Felipe L. Dario,
  • Mariana M. Fioravanti,
  • Alba Rodriguez-Nogales,
  • Julio Gálvez,
  • Clelia A. Hiruma-Lima

摘要

Introduction

Ulcerative colitis (UC) is the main representative of inflammatory bowel diseases (IBD) are chronic conditions characterized by intestinal inflammation, caused by the overproduction of pro-oxidant species and an immune response that damages the gut mucosa.

Objective

To evaluate the anti-inflammatory and protective effect of Citral, a monoterpene, on in vitro and in vivo models of UC.

Methodology

Male C57BL/6J mice were used for DSS 3%-induced UC for 5 days in drinking water. Concomitantly, daily oral citral (25, 100, and 300 mg/kg, p.o.) or vehicle was administered. Colonic segments were collected to evaluate neutrophil infiltration, lipid peroxidation, and the expression of antioxidant markers. NCM-356 and RAW-294 cells were stimulated with LPS (10 and 100 ng/mL, respectively). Cell viability, nitrite levels, scratch wound healing assay, and gene expression of inflammatory and growth factors were assessed.

Results

Acute treatment with citral (100 and 300 mg/kg) exhibited an anti-colitis effect by reducing the disease activity index (DAI) score compared to that in the DSS-vehicle group. This response was mediated by a significant reduction in myeloperoxidase activity and thiobarbituric acid reactive species levels, associated with an increase in superoxide dismutase activity, indicating anti-inflammatory and antioxidant activities (p < 0.05). The monoterpene reversed LPS-induced intestinal epithelial disturbance in the scratch wound healing process under different conditions and possibly reduced inos expression.

Conclusion

Citral treatment prevents the development of UC via anti-inflammatory, antioxidant, and healing effects.